



2021 ESG REPORT



TABLE OF CONTENTS

Introduction	2
Who We Are	2
Our Portfolio	2
Governance and Leadership	3
Governance of ESG	3
Board Diversity	3
ESG Performance Highlights	4
Environmental Management	5
Energy-Efficient Facilities	5
Waste Management	5
Human Capital	5
Environmental, Health, and Safety	5
Employee Training, Development, and Engagement	6
Diversity, Equity, and Inclusion	7
Governance and Responsible Business Practices	7
Business Ethics	7
Supply Chain Management	8
Product Quality	8
Data Security	8
Frameworks and Standards	9
United Nations Sustainable Development Goals	9
Sustainability Accounting Standards Board	10

INTRODUCTION

Who We Are

“Maravai” is a northern Italian word for “miracle.” Our mission is to enable the miracles of science.

We are a leading life sciences company that provides critical products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. From inventive startups to many of the world’s leading biopharma, vaccine, diagnostics, and cell and gene therapy companies, customers turn to us to address their complex discovery challenges and help them streamline and scale from research through clinical trials to commercialization. Our success is built on the ability of our proprietary technologies and products, provided under exacting quality standards, to reliably serve our customers’ needs for critical raw materials.

The core values that contribute to our success and the continued growth of our organization are: *Adaptability, Open Communication, Quality Mindset, Work Together, Workplace Awareness, and Reward.*

Throughout our organization, we think and act sustainably by using business practices that ensure safety, efficiency, and social responsibility in a manner that protects our employees, communities, shareholders, and the environment, both now and in the future.

While acting as a good corporate citizen has always been core to our culture, we are pleased to publish our inaugural ESG report highlighting current capabilities and initiatives. We recognize we are at the early part of a continual journey, and we look forward to periodically sharing updates on our progress in social and environmental areas important to our stakeholders, including investors, employees, customers, suppliers, and the communities in which we operate.

Our Portfolio

Two key business units make up the fabric of Maravai: Nucleic Acid Production and Biologic Safety Testing. These business units are comprised of the following portfolio companies:

NUCLEIC ACID PRODUCTION



TriLink BioTechnologies

in San Diego, California is a leading contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, NTPs, and mRNA capping analogs. TriLink has scale-up expertise and unique mRNA, oligonucleotide, and plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic, and biopharmaceutical breakthroughs. Biopharma companies turn to TriLink as a critical supplier of modified nucleic acids and as a CDMO partner to help them move from early research into clinical trials.



Glen Research,

headquartered in Sterling, Virginia, is a leading provider of reagents for DNA and RNA oligonucleotide synthesis, labeling, and modification. Glen supplies its reagents to researchers investigating diverse genetic diseases and disorders; businesses and organizations developing new genetic therapies; and biopharmaceutical, diagnostic, and life science OEM partners who incorporate Glen Research offerings into their own products.

BIOLOGIC SAFETY TESTING



Cygnus Technologies,

located in Southport, North Carolina, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives, and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval, and commercial release. The company provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes.

To learn more about each of our [portfolio companies](#), please visit our website.

Governance and Leadership

GOVERNANCE OF ESG

Our Board of Directors (Board) sets high standards for our employees, officers, and directors and believes in the importance of sound corporate governance. Our Board is responsible for business strategy and oversight of major risks to our business, including discussing our position on issues related to sustainability and environmental, social, and governance (ESG), as articulated in our [Corporate Governance Guidelines](#).

COMPENSATION AND NOMINATING COMMITTEE

In 2021, we amended the charter of the Compensation and Nominating Committee to include the review and oversight of ESG matters. The committee will report to the full Board on ESG strategy and progress on an annual basis.


ESG MANAGEMENT COMMITTEE

We also established an ESG Working Group at the management level comprised of senior representatives from Legal, Supply Chain Management, Quality, Investor Relations, Human Resources and Environmental, Health, and Safety (EHS) to further advance our ESG program.


BOARD DIVERSITY

In order for our Board to effectively guide us to long-term sustainable, dependable performance, we believe it should be composed of individuals with experience in the many disciplines that impact our business. We consider criteria such as independence, diversity, professional experience, and skills in the context of the needs of the board. In addressing issues of diversity in particular, the Compensation and Nominating Committee considers a nominee’s differences in gender, age, ethnicity, race, tenure, and qualifications. We believe that diverse backgrounds and viewpoints are key attributes for director nominees and helps the Board best serve the long-term interests of our shareholders. Of our eleven-member board, three directors are female, and one director identifies as ethnically diverse.

Board Gender Diversity



For more information, please view our latest [proxy statement](#).



ESG Performance Highlights*



ENVIRONMENT

DEVELOPED an [Environmental Policy](#) with a commitment to reduce our environmental impact and continually improve our environmental performance.

PARTNERED with a supply chain mapping company to create a traceable and transparent supply chain incorporating environmental and social aspects, including human rights, more formally into our purchasing and partnering decisions.

IMPLEMENTED data collection to establish our baseline environmental performance regarding the use of energy, water, raw materials, waste, and greenhouse gas (GHG) emissions.



HUMAN CAPITAL

EXPANDED our Employee Health and Safety (EHS) management system with a new online incident reporting system, including severity rating, root cause identification and corrective actions, and we introduced safety as an employee core competency in performance evaluations.

RECEIVED 90% overall participation in our latest employee engagement survey, with 75% of employees indicating satisfaction and enjoyment of their job. New programs, such leadership training for all managers, were implemented to address gaps.

INCLUDED in the State Street Global Advisors Diversity Index with our leadership team of 4 men and 4 women. Our employee population is 56% male and 44% female, and a majority of our employees, or 54%, identify as racially or ethnically diverse. We are committed to ensuring an open and inclusive work environment for all.



BUSINESS MODEL AND INNOVATION

RECEIVED ISO 9001:2015 certification for quality management at all of our facilities, which are supported by comprehensive quality programs and systems.

SUPPORTED COVID-19 vaccine development efforts: TriLink provided CleanCap® to multiple major global pharmaceutical and biopharma companies for their mRNA vaccine development programs, and TriLink and Glen Research supplied critical reagents to the world's major diagnostic companies.

PARTICIPATED in leading supply chain industry partnerships such as the Association for Supply Chain Management (ASCM), the Bio Supply Management Alliance (BSMA), and Biocom California Institute to enhance thought leadership and promote collaboration.



COMMUNITY RELATIONS

PROVIDED \$100,000 to local coronavirus relief efforts in each of our locations. A team of employees at each site determined where the donations were directed to make the most difference in the lives of people in each community.

SUPPORTED the nonprofit organization Voices for Children with a \$25,000 donation, funding ten Court Appointed Special Advocates (CASAs) for a year for children who enter foster care due to abuse, neglect, or abandonment.

PROVIDED philanthropic funds to each of our sites to affect local change and matched voluntary employee donations for Black Lives Matter.

Environmental Management

Our [Environmental Policy](#) details our commitment to reducing our environmental footprint and improving our environmental performance. It is an integral part of our business strategy and operating model, and incorporates regular review points. We encourage customers, suppliers, and other stakeholders to do the same.

We recognize that the first step in improving environmental performance is to understand and calculate baseline consumption. In 2021, we implemented a centralized application for tracking energy, waste, and water usage metrics on a go-forward basis at each of our locations. By the end of 2021, this baseline will help us identify and set goals around key environmental performance indicators.

ENERGY-EFFICIENT FACILITIES

Our largest location in San Diego, California is equipped with efficient LED lighting with automatic dimming, ENERGY STAR-certified equipment, and a central high-efficiency HVAC system.

To support our employees in making environmentally friendly transportation choices, we implemented six electric vehicle stations at our San Diego facility with plans to add more. Our parking lot has 49 parking spots or 8% of spaces dedicated to carpool and zero-emission vehicles, and we have a bike locker for employees who wish to bike to work.

WASTE MANAGEMENT

We engage a licensed third-party vendor to manage the proper collection, transportation, and disposal of our hazardous waste. At our office location as well as manufacturing and research sites, we have recycling initiatives for cardboard and consumer recyclables such as boxes, cans, bottles, plastic containers/bags, and wooden pallets. Pallets are recycled, reused, or returned to our carriers. We also collect and properly dispose of e-waste such as batteries, monitors, and laptops.

Human Capital

Our talented employees drive our mission and share core values that both stem from and define our culture. The core values that contribute to our success and the continued growth of our organization are: *Adaptability, Open Communication, Quality Mindset, Work Together, Workplace Awareness, and Reward.*

ENVIRONMENTAL, HEALTH, AND SAFETY

Our strong commitment to the health, safety, and wellbeing of our employees is evident in our Environmental, Health, and Safety (EHS) program where we focus on prevention.

Our [EHS Policy](#) covers our global operations and aligns our activities with the International Organization for Standardization (ISO) framework. We expect all employees, directors, contractors, and suppliers to follow this policy.

OCCUPATIONAL HEALTH AND SAFETY

We promote a culture of safety at Maravai and encourage employees to report hazards or potential workplace issues. All employees exposed to potential hazards are required to complete annual health and safety training, including laboratory chemical safety, hazard communication, and hazardous waste management.

To better track, report, and improve upon occupational health and safety, we have implemented a health and safety management system that includes an online incident reporting platform across all sites. To measure safety performance, we assess recordable case rates, early reporting of injuries and illnesses, and compliance training, among others. We have over thirty EHS standard operating procedures (SOPs) that govern our program, and in 2021 we introduced Safety and Workplace Awareness as a new core competency in the performance evaluation process of employees. Our Illness and Injury Prevention Program (IIPP) is updated annually and approved by our executive team. All employees are trained on the IIPP on an annual basis.



We track total recordable incident rate (TRIR) and days away from work (DART), and report these metrics to the Occupational Safety and Health Administration (OSHA). In 2020, our recordable injuries decreased by 14% from 2019, and our OSHA recordable injury rate decreased by 34%. If an occupational health and safety incident with an employee does occur, leadership is notified, an investigation is completed, and corrective actions are identified and implemented. Our Director of EHS reports metrics and progress to the Chief Executive Officer (CEO) annually, meets quarterly with the company Chief Operating Officers (COOs), and meets monthly with Senior Operations Leadership.

EHS compliance audits conducted by a third-party are scheduled at least annually. We completed two compliance-based audits in 2020, as well as two COVID-19 exposure risk assessments to ensure safety throughout our operations.

EMERGENCY PREPAREDNESS AND COVID-19 RESPONSE

As part of our emergency response program, we conduct annual emergency evacuation drills and training for all employees at all sites. In response to COVID-19, we implemented an exposure control program at our California sites, conducted risk assessments, and established a COVID-19 task force to monitor and comply with all state and federal regulations.

As the COVID-19 pandemic hit, our first responsibility was to our employees. We instituted new processes, guidelines, and preparedness measures within the context of our subsidiaries' unique culture and geographies. For example, employees at our TriLink facilities received free weekly mandatory testing, and we instituted contract tracing devices in our offices. The well-being effort did not stop with physical protocols, and also included outreach efforts focusing on the mental health of our employees on topics such as anxiety, depression, sleep, stress, and substance abuse. Through our employee assistance program, employees are offered up to three sessions with licensed professionals as well as additional online resources. We have spent over \$2 million throughout the COVID-19 pandemic to help keep our employees safe. In addition to the resources and initiatives we established during this time, we continue to offer support through services such as confidential counseling for employees and family members, monthly wellness challenges, childcare resources, and employee equity.

Using creative engagement programs, we have continued to educate our employee base and address key questions to help lessen fear surrounding the vaccine. As of June 2021, 88% of our employees were vaccinated without mandate.

We are proud of our efforts to help curb the spread of the disease through our role in research, testing, and manufacturing of products that assist in the vaccine development process. Our CleanCap® technology is a key raw ingredient in the first FDA-licensed COVID-19 vaccine. To read more about our efforts, please see our recent [SEC filings](#).

EMPLOYEE TRAINING, DEVELOPMENT, AND ENGAGEMENT

Our skilled and motivated employees are the foundation of our success and the catalyst for our growth. As of June 30, 2021, approximately 22% of our workforce have earned advanced degrees and all employees receive rigorous on-the-job training. As part of our talent recruitment strategy, we have developed an employee referral program with a referral rate of 12% as of June 2021. We believe the quality of our personnel is critical to ensuring the collaborative, long-standing relationships we maintain with many of our customers.

In 2021, we introduced a new online training platform with over 80 interactive courses. The curriculum varies according to the employee's role, responsibilities, and work environment, and EHS representatives coordinate the training matrix for each site. All employees also complete harassment prevention training and anti-discrimination training upon hire.

MANAGER TRAINING

In response to employee feedback in a global employee survey, we partnered with a leadership development consultant to provide a series of training to all managers on building and developing management skills. We also provide individual leadership coaching for all director and above positions.

In monthly one-on-one meetings, managers and employees are provided a forum to discuss professional development paths and opportunities for certification programs for career enhancement. We also conduct formal performance reviews for all regular employees aligned with career development in the first quarter of each year.

EMPLOYEE ENGAGEMENT

In 2019, we conducted an organization-wide employee survey to hear from our team across all subsidiaries and get a better understanding of issues that affect our morale, satisfaction, and engagement. Up to 90% of employees participated, and 75% of employees indicated satisfaction and enjoyment of their job. We also learned that 89% of employees feel their work contributes to the overall success of the company, and 81% agree that managers are fully capable of managing the team.



We listened and reacted to feedback, ultimately implementing new programs related to creating better avenues for communication, increased recognition for workplace excellence, and opportunities for training and leadership development.


A follow-up employee survey was launched in Q3 2021 to gain additional insights and promote employee engagement.

DIVERSITY, EQUITY, AND INCLUSION

Diverse ideas, people, and perspectives are the driving forces behind our innovative products and allow us to achieve our mission to improve human health by enabling the miracles of science.

We conduct annual diversity training as part of our employee onboarding with a module specifically on leveraging diversity and strengths in the workplace.

As of June 30, 2021, we had 494 full-time employees. 44% identify as female and 56% identify as male. Our Senior Management team consists of four women and four men.



We recognize that there are strengths afforded to our company by having a work force with diverse backgrounds, viewpoints, accomplishments, cultural background, and professional expertise. While we are in the process of assessing our formal approach to diversity and inclusion, it is our commitment to all employees to provide a workplace free from harassment and discrimination.

In 2021, we were recognized by State Street for our efforts to advance diversity within our leadership through inclusion in the State Street Diversity Index.

Governance and Responsible Business Practices

BUSINESS ETHICS

We require the highest standards of business ethics and integrity on the part of all employees, and we strive to comply with all applicable laws and regulations in the conduct of our business. All directors, officers, and employees are responsible for reviewing our [Code of Business Conduct and Ethics](#) (Code) and certifying annually that he or she has reviewed and is in compliance with the Code. The Code covers a range of topics including conflicts of interest, political contributions, honest and ethical conduct and fair dealings, and environmental protection.

We instituted a toll-free, confidential, and anonymous Ethics Hotline for all Maravai employees to facilitate reporting of conduct that might involve illegality or other violations of our policies and procedures. We aim to provide an avenue for employees to raise concerns and reassurance that they will be protected from reprisals or victimization for whistleblowing in good faith.

Information provided via the Ethics Hotline is reviewed by members of our Human Resources and Legal Department and reported to the Audit Committee of the Board of Directors. The number and nature of complaints, status of investigations, and resolution of complaints are reported to the Audit Committee on a quarterly basis. For more information, please review our [Whistleblower Policy](#).

ETHICAL MARKETING AND RESEARCH

Our commitment to ethical conduct also extends to interactions with our current and prospective customers and business partners. Marketing materials go through a legal and compliance review process and our commercial team undergoes sales and compliance training.

Our research and development activities are conducted responsibly, and we do not utilize stem cells in our products or supply them to customers.

SUPPLY CHAIN MANAGEMENT

We are committed to conducting our operations with integrity, respecting the rights of all individuals, and respecting the environment. We expect all suppliers who do business with Maravai and our subsidiaries to share these same commitments and meet the standards laid out in our [Supplier Code of Conduct](#), which is aligned with the United Nation's Guiding Principles on Business and Human Rights.

Our supply chain relies on a network of specialized suppliers and transportation companies, and capabilities at each of our sites are varied. We utilize two types of suppliers: those that provide direct materials and those that provide indirect materials. Direct materials are classified as life science raw materials, which are mostly chemicals and reagents. Indirect materials include lab services and supplies, capital and manufacturing equipment, Information Technology (IT) services, office supplies and general service suppliers.

SUPPLIER QUALIFICATION AND SELECTION

In selecting our supplier partners, we follow an assessment and qualification process that is overseen by our Vice President of Global Supply Chain. We determine the capability and fit of prospective suppliers through our supplier selection and qualification process, which assesses personnel experience and training, production and process controls, inspection and testing of material, corrective and preventative action, product labeling and packing, and processes around batch records and complaints. We also ensure suppliers adhere to certified quality assurance programs such as the International Organization for Standardization (ISO), when required, and inquire at the onset of the prospecting process.

SUPPLIER DIVERSITY

We are committed to establishing collaborative partnerships with qualified small and diverse suppliers, and we recognize the importance of ensuring our supply base reflects the diversity of the communities in which we live, work, and serve. We are in the process of assessing ways to measure supplier diversity to launch a more formalized supplier diversity program.

SUPPLY CHAIN SUSTAINABILITY

We recently incorporated ESG, particularly environmental factors, in our quarterly Business Reviews with major suppliers. After engaging with suppliers on this issue, we made some operational changes including shifting more of our spend, such as shipping, to suppliers with a strong commitment to ESG.

TriLink has partnered with a supply chain mapping firm, utilizing proprietary software that monitors suppliers with the objective of creating a traceable and transparent supply chain focusing on environmental, social, and human rights. This tool allows us to analyze custom risk heat maps and receive alerts for environmental risks in the supply chain. We are in the process of mapping our Tier I through Tier III suppliers to gain full transparency in our supply chain for business continuity and traceability.

PRODUCT QUALITY

We believe that the capacity to manufacture to stringent biopharmaceutical standards is constrained within the industry, and our ability to meet this demand sets us apart from our competition.

Our Quality Management System (QMS) guides our approach to product quality and includes comprehensive policies, procedures, and recordkeeping.

While all our sites are certified to ISO 9001:2015, our TriLink facility meets the additional Good Manufacturing Practice (GMP) requirements for active pharmaceutical ingredients (API) for clinical use. Many of our products also meet additional customer specific requirements outlined in quality agreements.

The Maravai Quality Team meets with the COOs and Site Leadership Team for quarterly quality management reviews to evaluate metrics as well as internal and external factors that could affect overall performance. To maintain our ISO certification, we go through an annual review and audit of our facilities to ensure compliance with the standard.

QMS TRAINING

All employees receive basic QMS training with additional quality management training provided based on job function. Training is tracked by management to ensure 100% completion. TriLink requires annual GMP training, and our other locations host ongoing training sessions to educate employees on topics such as corrective and preventative actions (CAPA), proper documentation practices, and other quality best-practices.

SUPPLIER QUALITY

Supplier quality, overseen by our Supplier Quality Management Team, is a key component of our QMS. We assess quality standards of existing suppliers on a regular basis and conduct periodic audits according to factors such as criticality of materials, total spend, prior issues with the supplier, and adherence to business requirements. New suppliers must fill out a quality questionnaire to evaluate their quality management capabilities, and the performance of existing suppliers is monitored according to our internal scoring system. We report these metrics in quarterly quality management reviews.

PRODUCT TRACEABILITY AND ANTI-COUNTERFEITING

We use a closed-loop enterprise resource planning system to protect against counterfeiting of our products. This system provides total traceability of all manufactured goods while supporting the functions of Purchasing, Planning, Warehousing, Distribution, and Order Management. Traceability is provided through a lot numbering system.

Quality and dedication to customer confidence, as well as an ongoing pledge to offer the highest standards of product support, are integral principles of our goal to serve as leaders in manufacturing the highest quality products.

DATA SECURITY





The Audit Committee of the Board is committed to the prevention, timely detection, and mitigation of the effects of cybersecurity threats or incidents to Maravai. The Audit Committee is updated by the Head of IT on a quarterly basis. Our Information Technology Policy governs all Maravai subsidiaries and is reviewed annually by the Chief Financial Officer (CFO) and Head of IT. We use security best practices to guide our security program, and we conduct annual employee training for all Maravai employees on cybersecurity threat avoidance.

FRAMEWORKS AND STANDARDS

In developing this report, we relied upon the Sustainability Accounting Standards Board (SASB) to help us understand the areas that may be most relevant to our investors and aligned our business activities to the United Nations Sustainable Development Goals (SDGs). We also performed a benchmarking analysis to help us understand trends and best practices in the industry.

United Nations Sustainable Development Goals

The United Nations Sustainable Development Goals (SDGs) were established in 2015 in an effort by world leaders to end poverty, protect the planet, and seek to ensure prosperity for all. After an examination of the 17 goals and their relevance to our business, we have begun to align our ESG strategy to the following SDGs.

RELEVANT SDG	MARAVAI ALIGNMENT
 <p>Goal 3: Good Health and Well-Being <i>Ensure healthy lives and promote well-being for all at all ages</i></p>	<p>This SDG is manifested in our mission to improve human health by enabling the miracles of science. Our products, practices, and commitment to quality allow our customers to improve the health and well-being of people across the globe. We are proud to be a key raw ingredient in the first FDA-licensed mRNA COVID-19 vaccine.</p>
 <p>Goal 5: Gender Equality <i>Achieve gender equality and empower all women and girls</i></p>	<p>At Maravai, diversity of talent, ideas, and perspectives strengthen our leadership position within our industry. We live the commitment to this SDG through representation of women and minorities on our board and in senior management roles. Our employee population is 57% racially and ethnically diverse, and we are honored to be included in the 2021 State Street Gender Diversity Index.</p>
 <p>Goal 8: Decent Work and Economic Growth <i>Promote sustained, inclusive, and sustainable economic growth; full and productive employment; and decent work for all</i></p>	<p>Our philosophy is that a skilled and motivated employee base is the foundation of our success. We deliver on our commitment to employee growth with pathways to promotions, training opportunities, and leadership development courses. We are proud that 89% of employees feel their work contributes to the company's success.</p>
 <p>Goal 9: Industry, Innovation, and Infrastructure <i>Build resilient infrastructure, promote inclusive and sustainable industrialization, and foster innovation</i></p>	<p>Our innovative thinking across our two business units – Nucleic Acid Production and Biologic Safety Testing – position us as leaders who provide critical life science products to startups, research organizations, and large-scale biopharmaceuticals, helping to improve outcomes across the healthcare space.</p>

Sustainability Accounting Standards Board

The Sustainability Accounting Standards Board (SASB) has identified the ESG issues that are most likely to affect the long-term financial performance of companies within a specific industry. Below are the disclosure topics and accounting metrics associated with our industry, Biotechnology and Pharmaceuticals. We have also included discussion around applicability of each metric to our business, and a reference for where you can find more information within the report.

TOPIC	ACCOUNTING METRIC	SASB CODE	LOCATION IN ESG REPORT
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	HC-BP-510a.1	Business Ethics
	Description of code of ethics governing interactions with health care professionals	HC-BP-510a.2	
Ethical Marketing	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	HC-BP-270a.1	Business Ethics
	Description of code of ethics governing promotion of off-label use of products	HC-BP-270a.2	
Employee Recruitment, Development & Retention	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	HC-BP-330a.1	Employee Training, Development, and Engagement
	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	HC-BP-330a.2	
Supply Chain Management	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	HC-BP-430a.1	Supply Chain Management
Counterfeit Drugs	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	HC-BP-260a.1	Product Quality, Supply Chain Management
	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	HC-BP-260a.2	
	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	HC-BP-260a.3	
Safety of Clinical Trial Participants	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	HC-BP-210a.1	Not applicable to our business
	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	HC-BP-210a.2	
	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	HC-BP-210a.3	
Access to Medicines	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	HC-BP-240a.1	Not applicable to our business
	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	HC-BP-240a.2	
Affordability & Pricing	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	HC-BP-240b.1	Not applicable to our business
	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	HC-BP-240b.2	
	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	HC-BP-240b.3	
Drug Safety	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	HC-BP-250a.1	Not applicable to our business
	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	HC-BP-250a.2	
	Number of recalls issued, total units recalled	HC-BP-250a.3	
	Total amount of product accepted for take-back, reuse, or disposal	HC-BP-250a.4	
	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	HC-BP-250a.5	